1. Home
  2. SPCB vs VERU Comparison

SPCB vs VERU Comparison

Compare SPCB & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SuperCom Ltd. (Israel)

SPCB

SuperCom Ltd. (Israel)

HOLD

Current Price

$7.91

Market Cap

45.3M

Sector

Technology

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.44

Market Cap

41.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPCB
VERU
Founded
1988
1971
Country
Israel
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.3M
41.7M
IPO Year
2004
1996

Fundamental Metrics

Financial Performance
Metric
SPCB
VERU
Price
$7.91
$2.44
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
37.8K
49.0K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
$27.13
N/A
P/E Ratio
$10.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.10
$0.36
52 Week High
$13.57
$4.59

Technical Indicators

Market Signals
Indicator
SPCB
VERU
Relative Strength Index (RSI) 41.80 46.03
Support Level $7.75 $2.15
Resistance Level $9.86 $2.70
Average True Range (ATR) 0.39 0.13
MACD -0.05 -0.02
Stochastic Oscillator 13.27 16.67

Price Performance

Historical Comparison
SPCB
VERU

About SPCB SuperCom Ltd. (Israel)

SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: